IN2010KO00035A - - Google Patents

Info

Publication number
IN2010KO00035A
IN2010KO00035A IN35KO2010A IN2010KO00035A IN 2010KO00035 A IN2010KO00035 A IN 2010KO00035A IN 35KO2010 A IN35KO2010 A IN 35KO2010A IN 2010KO00035 A IN2010KO00035 A IN 2010KO00035A
Authority
IN
India
Application number
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to PCT/IB2011/050822 priority Critical patent/WO2011086541A1/en
Priority to IN35KO2010 priority patent/IN2010KO00035A/en
Publication of IN2010KO00035A publication Critical patent/IN2010KO00035A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN35KO2010 2010-01-15 2011-02-25 IN2010KO00035A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IB2011/050822 WO2011086541A1 (en) 2010-01-15 2011-02-25 Novel polymorph of nilotinib monohydrochloride monohydrate
IN35KO2010 IN2010KO00035A (zh) 2010-01-15 2011-02-25

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN35KO2010 IN2010KO00035A (zh) 2010-01-15 2011-02-25

Publications (1)

Publication Number Publication Date
IN2010KO00035A true IN2010KO00035A (zh) 2016-09-02

Family

ID=43828136

Family Applications (1)

Application Number Title Priority Date Filing Date
IN35KO2010 IN2010KO00035A (zh) 2010-01-15 2011-02-25

Country Status (2)

Country Link
IN (1) IN2010KO00035A (zh)
WO (1) WO2011086541A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2010CH03577A (zh) * 2010-11-26 2012-07-20 Hetero Research Foundation
US9061028B2 (en) * 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
EP2906554A4 (en) 2012-10-15 2016-06-29 Apotex Inc SOLID FORMS OF NILOTINIB HYDROCHLORIDE
AU2013333953B2 (en) * 2012-10-19 2017-08-31 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
EP3461818A1 (en) 2013-04-24 2019-04-03 Dr. Reddy's Laboratories Ltd. Polymorphic forms of nilotinib hydrochloride
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
US9926296B2 (en) 2014-08-08 2018-03-27 Dr. Reddy's Laboratories Limited Process for the preparation of polymorphic forms of nilotinib hydrochloride
CA2964198C (en) 2014-10-16 2023-03-14 Apotex Inc. Solid forms of nilotinib hydrochloride
EP3404025B1 (en) * 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
EP3877379A4 (en) * 2018-11-05 2022-08-31 Laurus Labs Limited CRYSTALLINE FORM OF NILOTINIB HYDROCHLORIDE, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION CONTAINING IT

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
EP2262793B1 (en) * 2008-11-05 2012-10-03 Teva Pharmaceutical Industries Ltd. Nilotinib hci crystalline forms

Also Published As

Publication number Publication date
WO2011086541A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
BR112013008959A2 (zh)
BR112012029986A2 (zh)
BR112012030039A2 (zh)
BR112012028408A2 (zh)
BR112012026492A2 (zh)
BR112012027808A2 (zh)
BR112012024897A2 (zh)
BR112012019354A2 (zh)
BR112012025307A2 (zh)
BR112012002126A2 (zh)
BR112012026946A2 (zh)
BR112012017960A2 (zh)
BR112012025482A2 (zh)
BR112013006400A2 (zh)
BR112012031826A2 (zh)
BR112012028186A2 (zh)
BR112012025577A2 (zh)
BR112012023249A2 (zh)
BR112012016456A2 (zh)
BR112012018256A2 (zh)
BR112012027015A2 (zh)
BR112012025308A2 (zh)
BR112012027945A2 (zh)
BR112012024872A2 (zh)
BR112012023265A2 (zh)